New! Make Your CRM Smarter with Best-In-Class Intent Data

Learn More!
Epivax

Epivax

EpiVax is a 21-year old privately held biotechnology company located in Providence, Rhode Island. Scientists at EpiVax, led by co-founders Annie De Groot, MD and Bill Martin, lead in the fields of immunogenicity risk assessment and computational vaccinology with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's broad portfolio of projects includes vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. EpiVax's proprietary in silico immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies.

Last updated on

About Epivax

Founded

1998

Estimated Revenue

$1M-$10M

Employees

11-50

Funding / Mkt. Cap

$7M

Category

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Location

City

Providence

State

Rhode Island

Country

United States

Tech Stack (93)

search

Payment

Audio / Video Media

Content Management System

Verified CDN

Devops And Development

Programming Languages And Frameworks

Communications

Platform And Storage

Business Intelligence And Analytics

Computer Networks

E-commerce

Customer Management